1. Home
  2. FEBO vs LEXX Comparison

FEBO vs LEXX Comparison

Compare FEBO & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fenbo Holdings Limited

FEBO

Fenbo Holdings Limited

N/A

Current Price

$0.72

Market Cap

7.9M

Sector

N/A

ML Signal

N/A

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$10.81

Market Cap

8.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEBO
LEXX
Founded
1993
2004
Country
Hong Kong
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.9M
8.7M
IPO Year
2022
2011

Fundamental Metrics

Financial Performance
Metric
FEBO
LEXX
Price
$0.72
$10.81
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
6.1K
73.0K
Earning Date
05-12-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$705,923.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
52.05
52 Week Low
$0.61
$0.35
52 Week High
$1.46
$14.37

Technical Indicators

Market Signals
Indicator
FEBO
LEXX
Relative Strength Index (RSI) 43.83 55.26
Support Level $0.66 $10.24
Resistance Level $0.76 $12.89
Average True Range (ATR) 0.03 1.46
MACD 0.00 -0.20
Stochastic Oscillator 42.86 31.65

Price Performance

Historical Comparison
FEBO
LEXX

About FEBO Fenbo Holdings Limited

Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: